The expression patterns of MALAT-1, NEAT-1, THRIL, and miR-155-5p in the acute to the post-acute phase of COVID-19 disease

Mohammad Abbasi-Kolli, Javid Sadri Nahandi, Seyed Jalal Kiani, Khadijeh Khanaliha, AliReza Khatami, Mohammad Taghizadieh, Ali Rajabi Torkaman, Kimiya Babakhaniyan, Farah Bokharaei-Salim

Iran University of Medical Sciences, Deputy of Health, Tehran, Iran
Tabriz University of Medical Sciences, Infectious and Tropical Diseases Research Center, Tabriz, Iran
Iran University of Medical Sciences, School of Medicine, Department of Virology, Tehran, Iran
University of Medical Sciences, Institute of Immunology and Infectious Diseases, Research Center of Pediatric Infectious Diseases, Tehran, Iran
Tabriz University of Medical Sciences, Center for Women’s Health Research Zahra, School of Medicine, Department of Pathology, Tabriz, Iran
Tehran University of Medical Sciences, School of Medicine, Department of Clinical Biochemistry, Tehran, Iran
Iran University of Medical Sciences, School of Nursing and Midwifery, Department of Medical Surgical Nursing, Tehran, Iran

ABSTRACT

Introduction: One of the hallmarks of COVID-19 is overwhelming inflammation, which plays a very important role in the pathogenesis of COVID-19. Thus, identification of inflammatory factors that interact with the SARS-CoV-2 can be very important to control and diagnose the severity of COVID-19. The aim of this study was to investigate the expression patterns of inflammation-related non-coding RNAs (ncRNAs) including MALAT-1, NEAT-1, THRIL, and miR-155-5p from the acute phase to the recovery phase of COVID-19.

Methods: Total RNA was extracted from Peripheral Blood Mononuclear Cell (PBMC) samples of 20 patients with acute COVID-19 infection and 20 healthy individuals and the expression levels of MALAT-1, NEAT-1, THRIL, and miR-155-5p were evaluated by real-time PCR assay. Besides, in order to monitor the expression pattern of selected ncRNAs from the acute phase to the recovery phase of COVID-19 disease, the levels of ncRNAs were re-measured 6–7 weeks after the acute phase.

Result: The mean expression levels of MALAT-1, THRIL, and miR-155-5p were significantly increased in the acute phase of COVID-19 compared with a healthy control group. In addition, the expression levels of MALAT-1 and THRIL in the post-acute phase of COVID-19 were significantly lower than in the acute phase of COVID-19. According to the ROC curve analysis, these ncRNAs could be considered useful biomarkers for COVID-19 diagnosis and for discriminating between acute and post-acute phase of COVID-19.
Introduction

The Coronavirus Disease Pandemic of 2019 (COVID-19) is caused by a novel coronavirus known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). At the moment, 239 million individuals have been infected with SARS-CoV-2, and much more than 4.8 million have died as a result of this infection.¹ In addition, the epidemic has triggered worldwide social and economic instability. SARS-CoV-2 is an enveloped virus with a positive non-segmented single-stranded RNA genome which belongs to Nidovirales order, Coronaviridae family, Betacoronavirus genus, and lineage B.² Because of the worldwide severity of the pathogen, the increased infection rate of SARS-CoV-2, and the limitation of effective treatment approaches, more research is needed to properly control their spread and to offer treatment alternatives.

Over 90% of the human DNA sequence is constantly transcribed, but only 2% of it produces proteins. The vast majority of transcripts are classified as non-coding RNAs (ncRNAs). According to their sequence length, ncRNAs are classified into long non-coding RNA (lncRNA) with size larger than 200 nucleotides (nt) and small non-coding RNA (sncRNA) with length less than 200 nt, such as microRNAs, which are both important epigenetic and sub-cellular regulatory elements that can be involved in complex cellular biological processes.³ Reportedly, IncRNAs may play essential regulatory functions in the interaction between virus and host, including regulation of host antiviral responses, direct and indirect roles in viral and host gene transcription, as well as regulation of the stability and translation of miRNAs.⁴ Also, it has been found that viral proteins can influence the expression level of cellular IncRNAs and microRNAs (miRNAs). As a result, changes in the expression level of these factors, directly and/or indirectly, can affect viral infection through regulating host innate immune responses, such as inflammation, and by regulating expression of both cellular and viral genes.⁵⁻⁷

MicroRNA-155-5p (miR-155-5p) has been characterized as an ancient immune cell regulator. MiR-155-5p is remarkable in the immune system because it can change the transcription of activated myeloid and lymphoid cells, regulating a wide range of biological processes from inflammation to immune response.⁸ Numerous research in recent years have demonstrated that miR-155-5p is evolutionarily conserved. Its expression is continuously increased in diverse cellular systems during viral infections in both animal and human models.⁹⁻¹⁰ Similarly, in animal models of Acute Respiratory Distress Syndrome (ARDS), increased miR-155-5p is associated with respiratory infections, illness severity, and greater mortality.¹¹,¹² Overall, evidence strongly suggests that miR-155 has a critical role as regulator of inflammation¹³ and during most viral infections, since the expression level of miR-155 is upregulated and regulates antiviral immune responses.²⁴

Nuclear Factor-kappa B (NF-κB) is a dimeric transcription factor involved in inflammation and has an important role in pathogenesis of several inflammatory disease such as Chronic Obstructive Pulmonary Disease (COPD) and COVID-19.¹⁵ Numerous ncRNAs such as miR-155-5p, MALAT-1, NEAT-1 and THRIL are involved in regulating the NF-κB signaling pathway.¹⁶ It has been reported that lncRNA MALAT-1 can control cytokine secretion in macrophages under inflammatory circumstances and promote inflammatory activity by interacting with the NF-κB signaling pathway.¹⁷,¹⁸ NEAT-1 is another lncRNA that has been shown to play a role in NF-κB signaling pathway and NEAT-1 inhibition prevented the activation of the NF-κB pathway.¹⁹ and induced expression of inflammatory-related cytokines such as IL-8 and IL-6.²⁰ Reportedly, NEAT-1 probably can help the inflammation-regulating ncRNA-mRNA network, and some factors linked with this network may be able to regulate inflammation by interacting with essential inflammatory mediators such as IL-6, TNF and muscarinic acetylcholine receptors.²¹⁻²³ THRIL is a newly described IncRNA that has been confirmed to interact with hnRNPL (Heterogeneous Nuclear Ribonucleoprotein L) and then controlling the expression of TNF-α with an important role in regulation of inflammation and immune response.²⁴,²⁵ THRIL induce the upregulation of NRP1 expression and further induce the modulation of the NF-κB signaling pathway.²⁶ As a result, the interaction between IncRNAs and targets (e.g., miRNAs, cellular factors and viral genes) has sparked researchers’ interests to investigate the potential biomarkers and/or therapeutic targets. Currently, our understanding of SARS-CoV-2 processes is limited, and there are no particular biomarkers associated with SARS-CoV-2 diagnosis or therapy. Since selected cellular ncRNAs (miR-155-5p,²⁷-³¹ MALAT-1,³²-³⁵ NEAT-1,²⁰,³⁶,³⁷ and THRIL,³⁸,³⁹) may play critical roles in immune response regulation and inflammation, we evaluated the expression pattern of IncRNAs (MALAT-1, NEAT-1 and THRIL) and miR-155-5p in Peripheral Blood Mononuclear Cells (PBMC) of SARS-CoV-2 infected individuals in both acute and post-acute stages and compared to healthy individuals.

Patients and methods

Patients’ selection

From June 2021 to July 2021, 20 patients with COVID-19 infection were recruited from the West Health Center in Tehran (related to Iran University of Medical Sciences [IUMS]) and enrolled in this cross-sectional survey. A peripheral blood sample of 6 mL was collected from these patients during the...
acute phase and again in the post-acute phase, and from 20 healthy controls.

It should be noted that the studied participants did not have co-infections with Human Immunodeficiency Virus (HIV), Human Cytomegalovirus (HCMV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV), and Mycobacterium tuberculosis. Furthermore, none of the subjects had underlying medical conditions.

**Ethical issues**

This study was approved by the ethics committee of IUMS (ethical code: IR. IUMS. REC.1400.381), and all of the participants filled written informed consent for blood specimen collection.

**Preparation of peripheral blood mononuclear cells (PBMCs)**

Collected peripheral blood from each subject was transferred into a tube containing Ethylenediaminetetraacetic Acid (EDTA) as anticoagulant and then separated by centrifugation. PBMCs were isolated based on the ficoll hyopaque density gradient centrifugation (Lymphocyte-H, Cedarlane, Hornby, Canada) technique according to the manufacturer’s instructions, and then the pellet of PBMCs was washed three times with phosphate-buffered saline (pH: 7.3±0.1), and finally resuspended with 350 μL of RNA maintenance solution (RNA-Later [Ambion, Inc., Austin, TX]), and kept at -80°C until extraction of the total RNA.

**Total RNA isolation and complementary DNA (cDNA) synthesis**

Total RNA was extracted from PBMC samples according to the manufacturer’s protocols with minor modifications. Briefly, after PBMC lysis with 1 mL QIAzol solution, 250 μL of chloroform was added to the lysate, shaken vigorously for one minute, and after 5–10 minutes of incubation at room temperature, centrifuged at 12,000 × g for 15 minutes at 4°C. The supernatant was aspirated and approximate 800 μL isopropanol was added and placed in the freezer overnight. The samples were centrifuged at 12,000 × g for 45 minutes at 4°C. One mL ethanol (100%) was added to the RNA pellet and the microtubes went up and down several times and centrifuged at 12,000 × g for 15 minutes at 4°C. The pellet of RNA was air-dried and dissolved with RNase/DNase free distilled water. The integrity and purity of the isolated RNA was evaluated using a Nano-Drop spectrophotometer (Thermo Scientific, Wilmington, MA) instrument, and then kept at -80°C until the test.

To determine the expression pattern of IncRNAs (MALAT-1, NEAT-1 and THRIL), as well as GAPDH and β-actin (as normalization controls for relative quantification), cdNA was synthesized using 350 ng of the total RNA as previously described in detail.45

**Expression analysis of genes using real-time PCR**

The expression patterns of IncRNAs (MALAT-1, NEAT-1 and THRIL), and also GAPDH (the expression level of this housekeeping gene was considered as reference gene)62 were determined by real-time Polymerase Chain Reaction (PCR) using a Rotorgene Q thermal cycler (Qiagen, Hilden, Germany) instrument. The assays were done on 20 μL reaction mixture including: 10 pmol of each primer (MALAT-1, NEAT-1, THRIL, GAPDH and β-actin), 8 μL nuclease free distilled water, 10 μL 2 × SYBR® Premix Ex Taq (Tli Plus) Master Mix (TaKaRa Bio Inc. Shiga, Japan) (Table 1) and one μL of cdNA as template.

The thermocycling conditions for real-time PCR were defined as follows: initial denaturing at 95°C for 15 minutes, and 40 cycles, including 15 seconds at 95°C, 30 seconds at 60°C, and 20 seconds at 72°C. The 2−ΔΔCt method was used for calculation of the relative expression values. All the specimens were tested in duplicate reactions.

**miRNA-155-5p expression analysis**

Total RNA was extracted (as described in the previous section) from PBMC samples. Complementary DNA (cdNA) was synthesized using 5 μg of the total RNA as previously described in detail.66 In the current study the expression of miR-155-5p was evaluated in PBMC specimens of SARA-CoV-2 infected patients in the two stages of disease (acute and post-acute phase) and of healthy controls based on available information.

| Table 1 - Primers used in this study for determining expression profile of long non-coding RNAs (IncRNAs). |
|----------------|----------------|----------------|----------------|
| Size/bp | Sequences | Name | Direction | Real-time PCR based on SYBR-Green I fluorescence |
| 76/6 | 5’-CTTCCCTAGGGAGATTTCAGG-3’ | MALAT-F | Forward primer | Real Time PCR for MALAT-1 |
| 116/6 | 5’-GCCCAACAGGACACACCTTCA-3’ | MALAT-R | Reverse primer | Real Time PCR for NEAT-1 |
| 121/6 | 5’-CTTCTCCTCTCATCCATTGCTCA-3’ | NEAT-F | Forward primer | Real Time PCR for THRIL |
| 163/6 | 5’-AAATTATGGAGCATGTTGGGATG-3’ | NEAT-R | Reverse primer | Real Time PCR for GAPDH |
| 73/0 | 5’-CTTGTAACAACGCATCTCATATT-3’ | β-actin-F | Forward primer | Real Time PCR for β-actin |

MALAT-1, Metastasis Associated Lung Adenocarcinoma Transcript 1; NEAT-1, Nuclear Paraspeckle Assembly Transcript 1; THRIL, TNF and HNRNPL Related Immunoregulatory Long non-coding RNA; GAPDH, Glyceraldehyde 3-Phosphate Dehydrogenase.
The real time PCR assay was carried out in final 20 μL volume, including 0.5 μL of specific forward primer, 0.5 μL of universal reverse primer, 10 μL of SYBR Green PCR Master Mix (TaKaRa, Kusatsu, Japan), 8 μL of nuclease-free water, and one μL of cDNA as template. The thermal profile of this assay (three steps with melt) was set at 95°C for two minutes as hold time, followed by 40 cycles of denaturation at 95°C for 15 seconds, annealing at 60°C for 20 seconds, and extension at 72°C for 25 seconds, and also melting curve analysis was determined at temperatures ranging from 55 to 99°C. This assay was performed using the Rotorgene Q thermal cycler (Qiagen, Hilden, Germany) instrument. The expression levels of miR-155-5p was normalized to Snord47 and 68 as reference RNA and the fold change was calculated by the Livak method. It should be noted that all reactions were done in triplicate.

Statistical analysis

Data were analyzed using SPSS version 16 (SPSS Inc., Chicago, IL, USA) and Prism 6.0 software (GraphPad, San Diego, CA, USA). Clinical and demographics characteristics were presented as n (%) for categorical variables and mean ± Standard Deviations (SD) for age, which were analyzed by Fisher’s exact test and Student t-Test, respectively. The Mann-Whitney U-test or the independent-samples t-test was used to compare the mean expression levels of ncRNAs (MALAT-1, NEAT-1, THRIL and miR-155-5p) between the COVID-19 groups with the healthy control group. The statistical difference of the mean level of ncRNAs between acute and post-acute phases of COVID-19 disease was compared using the paired sample t-test. The Receiver Operating Characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of ncRNA expression level in discriminating between study groups. The Spearman rank correlation was used to compare the association of variables. The Benjamini and Hochberg procedure was used to control for the false discovery rate. All statistical evaluations were two-tailed, and p-values less than 0.05 were considered significant.

Results

Characteristics of participants

Fifty SARS-CoV-2 infected patients (in both acute and post-acute phases of the disease) and 50 healthy individuals were enrolled in this cross-sectional study. These two studied groups were matched for sex and age. The mean age of studied patients with SARS CoV-2 infection was 36.1±10.9 (ranging between 22–67 years) and for healthy individuals was 36.2±12.1 (ranging between 23–67 years). The demographic parameters of the studied participants and clinical manifestations of patients with SARS-CoV-2 infection are summarized in Table 2.

Expression pattern of ncRNAs was significantly deregulated during COVID-19 disease

The expression level of MALAT-1, NEAT-1, THRIL, and miR-155-5p were examined in PBMC samples during acute and post-acute COVID-19 disease and healthy control subjects. In acute COVID-19 group, expression profiles of MALAT-1, THRIL and miR-155-5p were found significantly deregulated (p-value of < 0.05) when compared with healthy controls. In comparison to the control group, the acute COVID-19 group showed higher expression levels: 3.42-fold for the miR-155-5p, 2.27-fold for THRIL, and 2.12-fold for MALAT-1, respectively. Also,

| Table 2 – The demographic parameters of the studied participants and clinical manifestations of patients with SARS-CoV-2 infection. |
|---------------------------------|----------------|----------------|----------------|
| Parameters                        | Male (%)       | Female (%)     | Total (%)     | p-value     |
| Healthy individuals               |                |                |               |             |
| n (%)                             | 25 (50.0%)     | 25 (50.0%)     | 50 (100.0%)   | -           |
| Age                               | 37.2±13.3 (23–67) | 35.0±11.2 (24–59) | 36.2±12.1 (23–67) | 0.569 Student t test |
| SARS-CoV-2 infected participants  |                |                |               |             |
| n (%)                             | 25 (50.0%)     | 25 (50.0%)     | 50 (100.0%)   | -           |
| Age                               | 38.1±8.6 (28–53) | 34.0±12.9 (22–67) | 36.1±10.9 (22–67) | 0.415 Student t test |
| Clinical manifestations of patients with SARS-CoV-2 infection |                |                |               |             |
| Fever                             | 35 (70.0%)     | 30 (60.0%)     | 65 (65.0%)    | 1.000 Fisher’s exact test |
| Chills                            | 25 (50.0%)     | 35 (70.0%)     | 60 (60.0%)    | 0.650 Fisher’s exact test |
| Headache                         | 35 (70.0%)     | 40 (80.0%)     | 75 (75.0%)    | 1.000 Fisher’s exact test |
| Skeletal pain                    | 35 (70.0%)     | 35 (70.0%)     | 70 (70.0%)    | 1.000 Fisher’s exact test |
| Chest pain                       | 10 (20.0%)     | 15 (30.0%)     | 25 (25.0%)    | 1.000 Fisher’s exact test |
| Shortness of breath              | 10 (20.0%)     | 10 (20.0%)     | 20 (20.0%)    | 1.000 Fisher’s exact test |
| Decreased smell                  | 5 (10.0%)      | 25 (50.0%)     | 30 (30.0%)    | 0.141 Fisher’s exact test |
| Decreased taste                  | 10 (20.0%)     | 15 (30.0%)     | 25 (25.0%)    | 1.000 Fisher’s exact test |
| Confusion                        | 10 (20.0%)     | 15 (30.0%)     | 15 (15.0%)    | 1.000 Fisher’s exact test |
| Dry cough                        | 20 (40.0%)     | 30 (60.0%)     | 50 (50.0%)    | 0.658 Fisher’s exact test |
| Sputum cough                     | 10 (20.0%)     | 0 (00.0%)      | 10 (10.0%)    | 0.474 Fisher’s exact test |
| Runny nose                       | 15 (30.0%)     | 20 (40.0%)     | 35 (35.0%)    | 1.000 Fisher’s exact test |
| Cape of nose                     | 20 (40.0%)     | 25 (50.0%)     | 45 (45.0%)    | 1.000 Fisher’s exact test |
| Bleeding stomach                 | 0 (00.0%)      | 5 (10.0%)      | 5 (5.0%)      | 1.000 Fisher’s exact test |
| Gastrointestinal symptoms        | 25 (50.0%)     | 20 (40.0%)     | 45 (45.0%)    | 1.000 Fisher’s exact test |
there was no significant difference in the mean expression level of NEAT-1 between acute COVID-19 group and control group (Fig. 1A), (p-value > 0.05). The expression pattern of lncRNAs (MALAT-1, NEAT-1 and THRIL) in post-acute COVID-19 group was similar to the healthy control group, as shown in Figure 1A. However, the mean expression level of miR-155-5p in post-acute COVID-19 was higher than that of control subjects (2.49-fold change, p-value < 0.0001).

In order to identify a PBMC biomarker that could be applicable to distinguish the prognosis of COVID-19 disease, the PBMC level of the selected lncRNAs (MALAT-1, NEAT-1 and THRIL) and miR-155-5p were re-measured 6‒5 weeks after the acute phase of COVID-19. Mean expression level of MALAT-1 and THRIL were significantly down-regulated (-1.8-fold, p-value = 0.037 and -1.98-fold, p-value = 0.022, respectively) in post-acute phase of COVID-19 compared to acute phase of COVID-19 disease (Fig. 1B). However, there was no significant difference in the expression pattern of miR-155-5p, and THRIL between acute COVID-19 group and post-acute COVID-19 group (p-value > 0.05).

In the current study, the potential of ncRNAs (miR-155-5p, MALAT-1, NEAT-1 and THRIL) in discriminating between COVID-19 groups and healthy controls and between acute phase of COVID-19 and post-acute phase of COVID-19 was evaluated by the ROC curve analysis. According to results which are illustrated in Figure 2, miR-155-5p (AUC = 0.89, p-value < 0.0001), MALAT-1 (AUC = 0.81, p-value < 0.0001) and THRIL (AUC = 0.77, p-value = 0.003) are effective in distinguishing acute phase of COVID-19 from healthy controls. In the case of post-acute COVID-19 phase compared with healthy controls, the AUC value for miR-155-5p was 0.83 (p-value < 0.0001). Especially, the miR-155-5p showed an excellent AUC value. Lastly, PBMC THRIL and MALAT-1 were able to distinguish acute phase of COVID-19 from post-acute phase of COVID-19 disease with AUC value of 0.75 (p-value = 0.005) and 0.72 (p-value = 0.021), respectively (Fig. 2).

The correlation between clinical characteristics and relative expressions of ncRNAs

Hsa-miR-155-5p is one of the cellular miRNAs that may play a critical role in regulating inflammation and antiviral cellular defense in SARS-CoV-2 infection. Furthermore, it has been documented that some cellular lncRNAs, such as MALAT-1, cause modulating miR-155-5p expression. For this reason, to determine the correlation between the expression level of lncRNAs (MALAT-1, NEAT-1 and THRIL) and miR-155-5p, Spearman correlation analysis was performed. According to the result, a negative correlation was found between MALAT-1 level and level of miR-155-5p (r = -0.52, p-value < 0.0001), (Fig. 3A). However, there was no significant correlation between expression level of NEAT-1 and THRIL with miR-155-5p expression level (Fig. 2B and C).

To investigate the relationship among expression level of ncRNAs with demographic-clinical characteristics and by SARS-CoV-2 (RdRP and N) genes in the COVID-19 patients during acute COVID-19 disease, Spearman correlation coefficient
was carried out (Table 3). According to the result, there was a significant negative correlation between delta Ct of miR-155-5p and delta Ct of RdRp (r = -0.7, p-value < 0.001) and N genes (r = -0.61, p-value < 0.01) of SARS-Cov-2. Besides, a significant positive correlation was found among delta Ct of THRIL and NEAT-1 with dry cough (r = 0.57, and r = 0.46, respectively) and with sputum cough (r = 0.42 and r = 0.58, respectively). As well, a significant positive correlation was found between MALAT-1 and skeletal pain (r = 0.55, p-value < 0.01) More information is provided in Table 3.

### Discussion

Increasing evidence indicated that ncRNAs play a critical role in inflammation-related disorders by regulation of the diverse biological processes, such as the activation of inflammatory pathway signaling.\(^{50,51}\) Reportedly, ncRNAs cross-talking with immune cells can also regulate inflammation and immunological response. Further, due to growing understanding of the interactions between SARS-CoV-2 with host ncRNAs,\(^ {52,53}\) one could suggest that SARS-CoV-2 can alter the immunological pathway by deregulation of ncRNAs expression. Result of this research point out that the expression level of MALAT-1, NEAT-1, THRIL, and miR-155-5p, which are associated with inflammatory response, were significantly different between COVID-19 patients and healthy control subjects, as well as between acute and post-acute phase of COVID-19 disease. Recently, it was shown that expression level of MALAT-1 was

---

**Table 3** - Spearman’s correlation coefficient between the expression level of ncRNAs with expression level of SARS-CoV-2 genes (N and RdRp genes), demographic and clinical characteristics.

|               | MALAT-1 | NEAT-1 | THRIL | miR-155-5p |
|---------------|---------|--------|-------|------------|
| RdRp          | 0.43    | 0.28   | 0.4   | -0.7c      |
| N gene        | 0.35    | 0.24   | 0.33  | -0.61b     |
| Sex Age       | 0.09    | 0.17   | 0.07  | -0.05ns    |
| Bleeding      | 0.11    | 0.28   | 0.28  | -0.08ns    |
| Gastrointestinal symptoms | 0.37  | 0.02   | 0.16  | 0.08ns     |
| Decreased taste | -0.33 | 0.45   | 0.04  | 0.02ns     |
| Decreased smell | -0.05  | 0.07   | 0.14  | -0.18ns    |
| Cape of nose  | 0.12    | 0.3    | 0.41  | -0.07ns    |
| Runny nose    | 0.1     | 0.24   | 0.36  | -0.19ns    |
| Shortness of breath | -0.1  | 0.38  | 0.38  | 0.36ns     |
| Chest pain    | 0.09    | 0.43   | 0.46  | 0.3ns      |
| Sputum cough  | -0.32   | 0.58   | 0.42  | 0.41a      |
| Dry cough     | -0.2    | 0.46   | 0.57  | -0.31ns    |
| Skeletal pain | 0.55    | 0.13   | 0.2   | 0.001ns    |
| Chills        | 0.28    | 0.17   | 0.39  | 0.13ns     |
| Headache      | -0.18   | -0.2   | 0.13  | 0.33ns     |
| Confusion     | 0.07    | 0.36   | 0.17  | 0.13ns     |
| Fever         | 0.61    | 0.1    | -0.004| 0.2ns      |

* p < 0.05  
** p < 0.01  
*** p < 0.001; ns, not significant.
significantly upregulated in SARS-CoV-2-infected bronchial epithelial cells. In another study, Huang et al. reported that expressions of NEAT-1 and MALAT-1 were significantly increased in severe COVID-19 patients compared to mild COVID-19 patients and they suggested that NEAT-1 and MALAT-1 promote cellular damage and stress. In addition, an in vivo study reported that silencing MALAT-1 inhibited neutrophil chemotaxis by interleukin-8 and suppresses pulmonary epithelial cells apoptosis. All of these findings suggest that MALAT-1 is increased in lung cells of COVID-19 patients, promoting immune cell tax and subsequent harmful inflammation. MALAT-1 expression is also linked to macrophage activation and maturation into the M1 subtype, which is important in numerous pathological events, including inflammation. Besides, MALAT-1 can promote the expression of Maf and IL-10 in T-helper (Th) cells and eventually suppresses immunity against infection. Recently, Rodrigues et al. investigated the expression of miR-3142, MALAT-1, and NEAT-1 in nasopharyngeal swab and saliva specimens of COVID-19 patients. They observed that expression levels of the NEAT-1 and MALAT-1 in SARS-CoV-2 positive samples were higher than those of healthy controls. Further, they suggested that salivary NEAT-1 could act as a potential biomarker for distinguishing between healthy subjects from COVID-19 patients (AUC = 0.80). Similarly, our data reveal that the level of MALAT-1 was significantly overexpressed in the acute phase of COVID-19 disease compared to healthy subjects. However, the expression level of MALAT-1 was significantly decreased from the acute phase to the post-acute phase of COVID-19 disease.

NEAT-1, a pro-inflammatory IncRNA which is comparable genomically to MALAT-1, was found to increase inflammation through enhanced inflammasome assembly and processing. NEAT-1 promote inflammation by induction of inflammatory cytokines such as Interleukin-6 (IL-6). In response to SARS-CoV-2 infection, IL-6 is one of the key immune components. In nine cell types (M1 and M2 type macrophages, monocytes, CD4+ T cells, and CD8+ memory T cells) identified from severe COVID-19 patient Bronchoalveolar Lavage (BAL) samples, there was overexpression of NEAT-1. According to our findings, no significant difference was observed in PBMC level of NEAT-1 between the acute COVID-19 group and the control group, and also the mean expression level of NEAT-1 during the acute phase of COVID-19 was statistically similar to the post-acute phase of the disease. These results suggest that the immunological effect of NEAT-1 may be specific to the lung, i.e., where the infection and inflammation initiate. Besides, different results from previous studies were possible because of differences in the type of samples.

The IncRNA THRIL can be involved in immune response to viral infection largely through regulating TNF-α, IFN-β, IL8 expression and inflammatory response. Tumor Necrosis Factor (TNF), an activator of NF-κB signaling pathway, is a major inflammatory cytokine regulator in host defense against viral infection. THRIL directly modulates TNF-α, whereas THRIL induces other cytokines and chemokines, but the processes need to be further investigated. For the first time in this study, we explored the expression pattern of IncRNA THRIL in COVID-19. Similar to the expression level of MALAT-1, THRIL was significantly overexpressed in acute COVID-19 group compared to healthy samples. Comparison between acute and post-acute COVID-19 groups, the mean expression level of THRIL was significantly down-regulated during acute to post-acute phase. As well, the AUC value shows that PBMC THRIL can serve as a biomarker in the discrimination of COVID-19 patients from healthy subjects and those in the acute phase of COVID-19 from those in the post-acute phase of COVID-19 disease.

MiR-155-5p has been known as the ‘master of inflammation’ during COVID-19 disease and constitutes part of an immunopathological picture in COVID-19 disease. In inflammatory responses, miR-155-5p controls NF-κB signaling and plays a critical role in the modulating the immune response. The miR-155-5p expression is considered to be the initial step in the NF-κB signaling upregulation of the immune cascade and feeding back through the IKK signalosome complex and PI3K/Akt to further increase NF-κB. It has been reported that regulation of miR-155-5p levels by glucocorticoids, can be considered as one of the effective COVID-19 treatments. Although the expression level of miR-155-5p was upregulated in COVID-19 patients, there is no literature so far investigating miRNA-155 mechanism in COVID-19. However, preceding reports has demonstrated that miRNA-155 has a strong impact in NF-κB signaling. Our results are in line with previous studies in which the mean expression level of miR-150-5p in acute-COVID-19 subjects are significantly higher than in the healthy subjects and in post-acute COVID-19 group. In addition, according to ROC curve results for miR-150-5p, this miRNA may be considered a novel biomarker for acute COVID-19 disease diagnosis.

Conclusion

According to the findings of the present study, expression pattern of inflammation-related ncRNAs including MALAT-1, NEAT-1, and miR-150-5p were significantly different between COVID-19 patients and healthy subjects. In addition, the level of miR-150-5p, MALAT-1, and NEAT-1 were significantly down-regulated from the acute phase of COVID-19 to the post-acute phase of COVID-19. Aberrant expression of ncRNAs was found in COVID-19 disease, which maybe associated with the pathogenesis of SARS-CoV-2 and identification of these factors can be helpful in setting a basis for classification of disease conditions and acting as biomarkers and even be considered as a valuable therapeutic target for the treatment of COVID-19 diseases. Finally, the low number of samples in this study was the main limitation of our work. Hence, the assessment of these non-coding RNAs in a large population is needed.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

The authors of the current survey would like to thank all of the volunteers who have participated in this research. The
The present study was funded by Research Deputy of Iran University of Medical Sciences, Tehran, Iran with Grant number 20975.

REFERENCES

1. Sarvepalli SS, Cruz ABV, Chopra T, Salimnia H, Chandrasekar P. Striking absence of “usual suspects” during the winter of the Coronavirus Disease 2019 (COVID-19) pandemic 2020-2021. Infect Control Hospital Epidemiol. 2021:1–2.

2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–92.

3. Zhao Z, Sun W, Guo Z, Zhang J, Yu H, Liu B. Mechanisms of lncRNA/microRNA interactions in angiogenesis. Life Sci. 2020;254:116900.

4. Liu W, Ding C. Roles of LncRNAs in viral infections. Front Cell Infect Microbiol. 2017;7:205.

5. Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucl Acids Res. 2011;39:5157–63.

6. Chen J, Zhou Y, Li H. lncRNA and miRNA in viral infection. Virus Res. 2018;257:25–32.

7. Youssefpouran S, Mostafaei S, Manesh PV, Iraniar F, Bokharaei-Salim F, Nahand JS, et al. The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker. Microb Pathog. 2020;147:104355.

8. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: an ancient regulator of the immune system. Immunol Rev. 2013;253:146–57.

9. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007;104 (5):1604–9.

10. Goncalves-Alves E, Saferding V, Schliehe C, Benson R, Saferding V, Schliehe C, Benson R, et al. MicroRNA-155 controls hTLR7 expression during viral infection. Front Immunol. 2019;10:1367.

11. Wu Z, Hao R, Li P, Zhang X, Liu N, Qiu S, et al. MicroRNA expression profile of mouse lung infected with 2009 pandemic H1N1 influenza virus. PLoS One. 2013;8:e74190.

12. Woods PS, Doolittle LM, Rossa LE, Nana-Sinkam SP, Tili E, Davis IC. Increased expression of microRNA-155-5p by alveolar type II cells contributes to development of lethal ARDS in H1N1 influenza A virus-infected mice. Virology. 2020;545:40–52.

13. Xiaoyan W, Pais EMA, Lan L, Jingrui C, Lin M, Fordjour PA, et al. MicroRNA-155: a novel armamentarium against inflammatory diseases. Inflammation. 2017;40:708–16.

14. Jafarzadeh A, Naseri A, Shojaie L, Nemati M, Jafarzadeh S, Baghi HB, et al. MicroRNA-155 and antiviral immune responses. Int Immunopharmacol. 2021;101:108188.

15. Alharbi KS, Fuloria NK, Fuloria S, Rahman SB, Al-Malki WH, Shaikh MAJ, et al. Nuclear factor-kappa B and its role in inflammatory lung disease. Chemico-Biolog Interact. 2021:109568.

16. Chew CL, Conos SA, Unal B, Tergaonkar V. Noncoding RNAs: master regulators of inflammatory signaling. Trends Molec Med. 2018;24:66–84.

17. Gong Y-P, Zhang Y-W, Su X-Q, Gao H-B. Inhibition of long noncoding RNA MALAT1 suppresses high glucose-induced apoptosis and inflammation in human umbilical vein endothelial cells by suppressing the NF-κB signaling pathway. Biochem Cell Biol. 2020;98:665–75.

18. Zhou H-J, Wang L-Q, Wang D-B, Wu J-B, Zhu Y, Xu Q-S, et al. Long noncoding RNA MALAT1 contributes to inflammatory response of microglia following spinal cord injury via the modulation of a miR-199b/IKKα/NF-κB signaling pathway. Am J Physiol-Cell Physiol. 2018;315:C52–61.

19. Chen Y, Qiu J, Chen B, Lin Y, Chen Y, Xie G, et al. Long non-coding RNA NEAT1 plays an important role in sepsis-induced acute kidney injury by targeting miR-204 and modulating the NF-κB pathway. Int Immunopharmacol. 2018;59:252–60.

20. Zhang P, Cao L, Zhou R, Yang X, Wu M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10:1495.

21. Borovkova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature. 2000;405:458–62.

22. Shenhar-Tsarfaty S, Yayon N, Waiskopf N, Shapira I, Toker S, Zaltser D, et al. Fear and C-reactive protein co-synergize annual pulse increases in healthy adults. Proc Natl Acad Sci USA. 2015;112:E467–71.

23. Meydan C, Madrer N, Soreq H. The near dance of COVID-19: NEAT1, DANCER, and Co-modulated cholinergic RNAs link to inflammation. Front Immunol. 2020;11:590870.

24. Xu B, Jin X, Yang T, Zhang Y, Liu S, Wu L, et al. Upregulated lncRNA THRIL/TNFα signals promote cell growth and predict poor clinical outcomes of osteosarcoma. Oncotargets Therapy. 2020;13:119.

25. Li Z, Zhao C-T, Chang K-Y, Lin N, Patil VS, Shimizu C, et al. The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Nat Acad Sci. 2014;111:1002–7.

26. Kuai F, Zhou L, Zhou J, Sun X, Dong W. Long non-coding RNA THRIL inhibits miRNA-24-3p to upregulate neuropilin-1 to aggravate cerebral ischemia-reperfusion injury through regulating the nuclear factor-κB p65 signaling. Aging (Albany NY). 2021;13:9071.

27. Dickey LL, Hanley TM, Huffaker TB, Ramstead AG, O’Connell RM, Lane TE. MicroRNA 155 and viral–induced neuroinflammation. J Neuroimmunol. 2017;308:17–24.

28. Tili E, Michaille JJ, Wernicke D, Alder H, Costinean S, Volinia S, et al. Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA. 2014;111:1002–7.

29. Bhattacharya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C, et al. Elevated miR-155 promotes inflammatory cytokine expression by driving hyperexpression of interleukin-8. J Bioi Chem. 2011;286:11604–15.

30. Alois MS, Prater KE, Sopher B, Davidson S, Jaydev S, Garden GA. The pro-inflammatory microRNA miR-155 influences fibrillar β-Amyloid(1-42) catabolism by microglia. Glia. 2021;69:1736–48.

31. Zhou Y, Ma XY, Han JY, Yang M, Lv C, Shao Y, et al. Metformin regulates inflammation and fibrosis in diabetic kidney disease through TNC/TLR4/NF-κB pathway. World J Diabetes. 2021;12:19–46.

32. Puthanveetil P, Chen S, Feng B, Gautam A, Chakrabarti S. Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells. J Cell Mol Med. 2015;19:1418–25.

33. Zhao G, Su Z, Song D, Mao Y, Mao X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-κB. FEBS Lett. 2016;590:2884–95.

34. Yang H, Liang N, Wang M, Fei Y, Sun J, Li Z, et al. Long noncoding RNA MALAT1 is a novel inflammatory regulator in human systemic lupus erythematosus. Oncotarget. 2017;8:77400–6.

35. Biswas S, Thomas AA, Chen S, Aref-Eaghghi E, Feng B, Grond J, et al. MALAT1: an epigenetic regulator of inflammation in diabetic retinopathy. Sci Rep. 2018;8:6526.
36. Wang SM, Liu GQ, Xian HB, Si JL, Qi SX, Yu YP. LncRNA NEAT1 alleviates sepsis-induced myocardial injury by regulating the TLR2/NF-kB signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23:4898–907.

37. Dai W, Wang M, Wang P, Wen J, Wang J, Cha S, et al. lncRNA NEAT1 ameliorates LPS-induced inflammation in MG63 cells by activating autophagy and suppressing the NLRP3 inflammasome. Int J Mol Med. 2021;47:807–20.

38. Li Z, Chao TC, Chang KY, Lin N, Patil VS, Shimizu C, et al. The long noncoding RNA THRIL regulates TNFα expression through its interaction with hnRNPL. Proc Natl Acad Sci USA. 2014;111:1002–7.

39. Xu B, Jin X, Yang T, Zhang Y, Liu S, Wu L, et al. Upregulated lncRNA NEAT1 and MALAT1 are highly expressed in severe COVID-19 patients. Mol Oral Microbiol. 2021.

40. Zhang K, Mao T, He Z, Wu X, Peng Y, Chen Y, et al. Serum MALAT1 assumes signifying capacity in gastric cancer diagnosis. 2020.

41. Galamb O, Barták BK, Kalmár A, Nagy ZB, Szigeti KA, Tulassay Z, et al. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol. 2019;25:5026.

42. Qi H, Shen J, Zhou W. Up-regulation of long non-coding RNA THRIL in coronary heart disease: prediction for disease risk, correlation with inflammation, coronary artery stenosis, and major adverse cardiovascular events. J Clin Lab Anal. 2020;34:e23196.

43. Sun Y, Wen Y, Ruan Q, Yang L, Huang S, Xu X, et al. Exploring the association of long non-coding RNA expression profiles with intracranial aneurysms, based on sequencing and related bioinformatics analysis. BMC Med Genomics. 2020;13:147.

44. Dehghani-Deheji F, Hosseini Z, Mortazkar P, Khanaliha K, Alaei Z, et al. An NF-kB inhibitor alleviates sepsis-induced myocardial injury by regulating the TLR2/NF-kB signaling pathway. Braz J Infect Dis. 2021;26(3):102354.

45. Nakamura R, Ishii H, Endo K, Hotta A, Fujii E, Miyazawa K, et al. Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol. 2019;25:5026.

46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25:402–8.

47. Plowman T, Lagos D. Non-coding RNAs in COVID-19: emerging insights and current questions. Non-Coding RNA. 2021;7:54.

48. Vishnubalaji R, Shaath H, Alajez NM. Protein coding and long non-coding RNA (lncRNA) transcriptional landscape in SARS-CoV-2 infected bronchial epithelial cells highlight a role for interferon and inflammatory response. Genes. 2020;11:760.

49. Huang K, Wang J, Sun F, Cui H, Yang X, Wu M. The lncRNA Neat1 mediates both activation and repression of immune response genes. Science. 2019;364(6435):965–9.

50. Newton K, Manning G. Necrosis and inflammation. Ann Rev Biochem. 2016;85:743–63.

51. Wang W, Yang N, Yang Y-H, Wen R, Liu C-F, Zhang T-N. Non-coding RNAs: master regulators of inflammasomes in inflammatory diseases. J Inflamm. 2021;14:5023–50.

52. Donyavi T, Bohra-Karimi S, Baghi HB, Khanaliha K, Janat-Makan MA, Karimi B, et al. Acute and post-acute phase of COVID-19: analyzing expression patterns of miRNA-29a-3p, 146a-3p, 155-5p, and let-7b-3p in PBMC. Inter Immunopharmacol. 2021;97:107641.

53. Carpenter S, Aiello D, Atianand MK, Gandhi P, Ricci EP, Gandhi PP, et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science. 2013;341:789–92.

54. Rodriguez AC, Adamoski D, Genelhould G, Zhen F, Yamaguto GE, de Araujo Souza PS, et al. NEAT1 and MALAT1 are highly expressed in salvia and nasopharyngeal swab sample of COVID-19 patients. Mol Oral Microbiol. 2021.

55. Zhang P, Cao L, Zhou R, Yang X, Wu M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat Commun. 2019;10:1–17.

56. Hewitson JP, West KA, James KR, Rani GF, Dey N, Romano A, et al. Malat1 suppresses immunity to infection through promoting expression of maf and IL-10 in Th cells. J Immunol. 2020;204:2949–60.

57. Rodrigues AC, Adamoski D, Genelhould G, Zhen F, Yamaguto GE, de Araujo Souza PS, et al. NEAT1 and MALAT1 are highly expressed in salvia and nasopharyngeal swab sample of COVID-19 patients. Mol Oral Microbiol. 2021.

58. Huang K, Wang J, Sun F, Cui H, Yang X, Wu M. The lncRNA Neat1 mediates both activation and repression of immune response genes. Science. 2019;364(6435):965–9.

59. Newton K, Manning G. Necrosis and inflammation. Ann Rev Biochem. 2016;85:743–63.

60. Mann M, Mehta A, Zhao JL, Lee K, Marinov GK, Garcia-Flores Y, et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses. Nat Commun. 2017;8(1):1–13.

61. Group TRC. Dexamethasone in hospitalized patients with COVID–19 – preliminary report. New Engl J Med. 2020.

62. Garg A, Seeliger B, Derda AA, Xiao K, Gietz A, Scherf K, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Euro J Heart Fail. 2021;23:468–75.